For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

ECOG-ACRIN EA2165

Trial Overview

Official Title

Testing the Addition of the Drug Nivolumab after Surgery for High Risk Anal Cancer

Study Purpose

To find if adding the study drug, nivolumab (also known as OPDIVO), after standard chemotherapy and radiation will prevent the anal cancer from returning.

Diagnosis

Stage IIB, IIIA, or IIIC invasive squamous cell carcinoma of the anus or anorectum.

Eligibility

Must not have had prior potentially curative surgery for carcinoma of the anus.

Must be registered within 63 days following completion of standard chemoradiation for anal cancer.

Must have completed or plan on completing standard of care chemotherapy and radiation for their anal or anorectal cancer.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

  • Group 1: Will get the study drug Nivolumab. Nivolumab is given by an intravenous (IV) infusion over 30 minutes once every four weeks. Treatment will continue for a maximum of 6 months or 6 doses of nivolumab or until you have side effects, your cancer returns, or you decide to stop.
  • Group 2: Will be monitored with usual follow up.

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Phase
Phase II
Methodist Health System Trial Code
EA2165
Related Specialties